DOCSLIB.ORG

Alpha Blockers to Speed Ureteral

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alpha Blockers to Speed Ureteral Cochrane for Clinicians Putting Evidence into Practice These are summaries of Alpha Blockers to Speed Ureteral therapy plus standard therapy (hydration, reviews from the Cochrane Stone Passage pain killers, nonsteroidal anti-inflammatory Library. NATHAN HITZEMAN, MD, and SARAH drugs, corticosteroids, prophylactic antibi- This series is coordinated otics) with standard therapy plus placebo. by Corey D. Fogleman, WILLIAMS, MD, Sutter Health Family MD, Assistant Medical Medicine Residency Program, Sacramento, Others compared alpha blockers with cal- Editor. California cium channel blockers such as nifedipine A collection of Cochrane for (Procardia; 30 mg) or the antimuscarinic Clinicians published in AFP Clinical Question tolterodine (Detrol; 4 mg). is available at http://www. Do alpha blockers safely speed passage of The overall stone expulsion time was aafp.org/afp/cochrane. subcentimeter ureteral stones? three days shorter with alpha blockers than CME This clinical content with standard therapy, with a mean expul- conforms to AAFP criteria Evidence-Based Answer sion time of seven rather than 10 days. for continuing medical Compared with patients receiving standard When looking at stone-free status by the education (CME). See CME Quiz Questions on therapy (e.g., fluids, analgesics), placebo, or end of the study, patients taking alpha page 160. calcium channel blockers, patients receiving blockers had much improved clearance Author disclosure: No rel- alpha blockers had about three fewer days compared with those in standard therapy evant financial affiliations. to ureteral stone expulsion and were less (30 studies with 2,378 participants; rela- likely to be hospitalized. Adverse effects of tive risk [RR] = 1.48; number needed to alpha blocker therapy are generally tolerable. treat [NNT] = 4), and also when compared (Strength of Recommendation: A, based on head-to-head with patients taking calcium consistent, good-quality patient-oriented channel blockers (four studies with 3,486 evidence.) participants; RR = 1.19; NNT = 4.8). A Chinese RCT of 3,189 patients accounted Practice Pointers for most of the latter findings; the study was The prevalence of kidney stone disease has appropriately masked and considered at low increased in recent years and affects 5% risk of bias.2 to 10% of the population.1 Alpha blockers The benefits of alpha blockers were robust, relax smooth muscle and decrease intraure- irrespective of whether the stone was smaller teral pressures. The authors of this Cochrane than 5 mm or was 5 to 10 mm in diameter. meta-analysis evaluated the role of alpha Alpha blockers greatly reduced the need to blockers as a medical therapy to speed the hospitalize (four studies with 313 partici- passage of ureteral stones. pants; RR = 0.35; NNT = 4.2) and, to a more The authors identified 32 randomized modest degree, reduced the number of pain controlled trials (RCTs) and quasi-RCTs episodes and amount of pain medication with 5,864 participants. Participants used. were symptomatic adults with radiologi- Only five studies reported adverse effects. cally confirmed ureteral stones 10 mm or In these studies, about 10% of participants smaller. Exclusion criteria included urinary (88 out of 845) experienced dizziness, pal- tract infection, hydronephrosis, or other pitations, headache, rhinitis, retrograde underlying abnormalities of the kidney or ejaculation, fatigue and weakness, cutane- ureters. ous reaction, or postural hypotension. Most Alpha blockers used included tamsulosin adverse effects were mild and did not lead to (Flomax; 0.2 or 0.4 mg), alfuzosin (Uroxa- cessation of therapy. tral; 10 mg), doxazosin (Cardura; 4 mg), and Specialty guidelines published in 2007 terazosin (Hytrin; 2 or 5 mg); most stud- recommend use of alpha blockers to help ies used tamsulosin in a dosage of 0.4 mg pass subcentimeter ureteral stones in other- once daily. The majority of studies ran two wise stable patients.3 Duration of treatment to four weeks and compared alpha-blocker is not specified by the guidelines, but this 164Downloaded American from the Family American Physician Family Physician website at www.aafp.org/afp.www.aafp.org/afp Copyright © 2015 American AcademyVolume of Family 91, Physicians. Number For3 ◆the February private, noncom 1, 2015- mercial use of one individual user of the website. All other rights reserved. Contact [email protected] for copyright questions and/or permission requests. Cochrane for Clinicians Cochrane review suggests that passage should occur Practice Pointers within one month, if not two weeks. Family physicians The Diagnostic and Statistical Manual of Mental Disorders, should consider alpha blockers as first-line therapy for 5th ed., combines “opioid abuse” and “opioid depen- patients with otherwise uncomplicated subcentimeter dence” into the new diagnosis “opioid use disorder,” cat- ureteral stones. egorized as mild, moderate, or severe based on the number 1 SOURCE: Campschroer T, Zhu Y, Duijvesz D, Grobbee DE, Lock MT. Alpha- of positive symptoms. Pharmacologic treatment options blockers as medical expulsive therapy for ureteral stones. Cochrane for opioid use disorder include methadone and buprenor- Database Syst Rev. 2014;(4):CD008509. phine. Buprenorphine is usually prescribed as a combi- The practice recommendations in this activity are available at http:// nation formulation that includes the pharmacologically summaries.cochrane.org/CD008509. inactive naloxone, except in pregnancy when it is recom- mended that buprenorphine be used alone. Both metha- REFERENCES done and buprenorphine are intended to be administered 1. Ramello A, Vitale C, Marangella M. Epidemiology of nephrolithiasis. in conjunction with psychosocial treatment, with the goal J Nephrol. 2000;13(suppl 3):S45-S50. of eliminating withdrawal symptoms and maintaining the 2. Ye Z, Yang H, Li H, et al. A multicentre, prospective, randomized trial: patient on a documented and regulated dosage. Because comparative efficacy of tamsulosin and nifedipine in medical expul- buprenorphine is a partial agonist, there is a ceiling effect sive therapy for distal ureteric stones with renal colic. BJU Int. 2011; 108(2):276-279. to the level of respiratory depression or sedation it can 3. Preminger GM, Tiselius HG, Assimos DG, et al.; EAU/AUA Nephroli- cause, reducing the risk of overdose. Buprenorphine may thiasis Guideline Panel. 2007 guideline for the management of ureteral be prescribed by primary care physicians who complete calculi. J Urol. 2007;178 (6):2418-2434. eight hours of training and receive a waiver from the Drug Enforcement Administration. Buprenorphine Maintenance vs. This analysis included 31 randomized controlled Methadone Maintenance or Placebo trials (5,430 participants) comparing buprenorphine for Opioid Use Disorder maintenance with placebo or methadone maintenance. Primary outcomes were retention in treatment and con- ELIZABETH SALISBURY-AFSHAR, MD, MPH, FAAFP tinued use of opioids as measured by self-report or uri- Heartland Health Outreach, Chicago, Illinois nalysis. Various dosing regimens were used. All dosages of buprenorphine were superior to placebo in treatment Clinical Question retention: 7 to 15 mg per day (relative risk [RR] = 1.74; Is buprenorphine maintenance treatment effective in the 95% confidence interval [CI], 1.06 to 2.87), and 16 mg management of opioid use disorder? or more per day (RR = 1.82; 95% CI, 1.15 to 2.90). Thus, given a baseline retention rate of 40% in those Evidence-Based Answer receiving placebo, the retention rate would increase to At dosages greater than 2 mg per day, buprenorphine approximately 70% in those receiving 7 to 15 mg of maintains treatment retention better than placebo. buprenorphine and to 73% in those using at least 16 mg (Strength of Recommendation: A, based on consistent, of buprenorphine daily. Only high-dosage buprenor- good-quality patient-oriented evidence.) At 16 mg or phine (at least 16 mg per day) was effective—and then, more per day, buprenorphine was found to reduce only mildly—in suppressing illicit opioid use when illicit substance use compared with placebo as moni- monitored by urinalysis (standardized mean difference tored by urinalysis. (Strength of Recommendation: B, [SMD] = –1.17; 95% CI, –1.85 to –0.49). based on inconsistent or limited-quality patient-oriented In studies comparing buprenorphine maintenance evidence.) with methadone maintenance, flexible dosing and fixed When flexible dosing (doses adjusted based on patient dosing were evaluated. In analyses of flexible dosing, symptoms) is used, the effectiveness of buprenorphine is buprenorphine was less effective than methadone in comparable to that of methadone in suppressing opioid treatment retention (RR = 0.83; 95% CI, 0.72 to 0.95), use. (Strength of Recommendation: B, based on incon- but there was no difference between groups in sup- sistent or limited-quality patient-oriented evidence.) pression of opioid use when monitored by urinalysis When fixed dosing (a set dose is given) of 7 mg or more (SMD = –0.11; 95% CI, –0.23 to 0.02). However, when is used, buprenorphine and methadone are equally fixed dosing was studied, medium (7 to 15 mg) and high effective as measured by retention in treatment and (16 mg or more) doses of buprenorphine were found to suppression of illicit opioid use. (Strength of Recom- be equivalent to medium (40 to 85 mg) and high (85 mg mendation: B, based on inconsistent or limited-quality or more) fixed doses of methadone in terms of retention patient-oriented evidence.) and
Load more

Recommended publications
  • Pharmacology in MS Advanced Practice Management
    Pharmacology in MS Advanced Practice Management Heidi Maloni APRN, BC [email protected] Objectives • Discuss basic principles of pharmacology, pharmacokinetics and pharmacodynamics. • Describe the pharmacotherapeutics of drugs used in MS • Identify the role of advanced practice nurse in MS pharmacological management. Advanced Practice Pharmacology Background • Pharmacology: study of a drug’s effects within a living system • Each drug is identified by 3 names: chemical, generic, trade or marketing name N-4-(hydroxyphenyl) acetamide; acetaminophen; Tylenol sodium hypochlorite; bleach; Clorox 4-(diethylamino)-2-butynl ester hydrochloride; oxybutynin chloride; Ditropan • Drugs are derived from: plants, humans, animals, minerals, and chemical substances • Drugs are classified by clinical indication or body system APN Role Safe drug administration Nurses are professionally, legally, morally, and personally responsible for every dose of medication they prescribe or administer Know the usual dose Know usual route of administration Know significant side effects Know major drug interactions Know major contraindication Use the nursing process Pregnancy Safety • Teratogenicity: ability to produce an abnormality in the fetus (thalidomide) • Mutogenicity: ability to produce a genetic mutation (diethylstilbestrol, methotrexate) Pregnancy Safety Categories • A: studies indicate no risk to the fetus (levothyroxan; low dose vitamins, insulin) • B: studies indicate no risk to animal fetus; information in humans is not available (naproxen;acetaminophen; glatiramer
    [Show full text]
  • Comparison of Different Alpha-Blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
    대한남성과학회지：제 29 권 제 3 호 2011년 12월 Korean J Androl. Vol. 29, No. 3, December 2011 http://dx.doi.org/10.5534/kja.2011.29.3.242 Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms Keon Cheol Lee1, Jong Gu Kim2, Sung Yong Cho1, Joon Sung Jeon1, In Rae Cho1 Department of Urology, 1Inje University Ilsanpaik Hospital, Goyang, 2Happy Urology Clinic, Ansan, Korea =Abstract= Purpose: We compared the efficacy and safety profiles of dose increase, traditional combination methods, and combining different alpha blockers in hypertensive males with lower urinary tract symptom (LUTS) refractory to an initial dose of 4 mg doxazosin. Materials and Methods: Between 2000 and 2005, 374 male patients with LUTS and hypertension unresponsive to 4 weeks of 4 mg doxazosin were enrolled. The subjects were randomly classified into 3 groups, 8 mg/day of doxazosin (D group), 4 mg of doxazosin plus 0.2 mg/day of tamsulosin (DT group), and 4 mg doxazosin plus 5 mg/day finasteride (DF group). Patients were evaluated based on their International Prostate Symptom Score (IPSS), quality of life (QOL), uroflowmetry and blood pressure (BP) and adverse events (AEs) at the baseline and 3 and 12 months after treatment. Results: The 269 patients (71.9%) were followed for at least 1 year (D group n=84, DT group n=115, and DF group n=70). The clinical parameters before and after initial 4 mg/day doxazosin were not different among the 3 groups. IPSS improvement after 3 months and maximal flow rate (Qmax) improvement after 3 and 12 months were significantly higher in the D and DT groups than the DF group (p＜0.05).
    [Show full text]
  • Airway Receptors
    Postgraduate Medical Journal (1989) 65, 532- 542 Postgrad Med J: first published as 10.1136/pgmj.65.766.532 on 1 August 1989. Downloaded from Mechanisms of Disease Airway receptors Peter J. Barnes Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6L Y, UK. Introduction Airway smooth muscle tone is influenced by many indirect action which, in part, is due to activation of a hormones, neurotransmitters, drugs and mediators, cholinergic reflex, since the bronchoconstriction may which produce their effects by binding to specific be reduced by a cholinergic antagonist. Other surface receptors on airway smooth muscle cells. mediators may have a bronchoconstrictor effect Bronchoconstriction and bronchodilatation may which, in the case of adenosine, is due to mast cell therefore be viewed in terms of receptor activation or mediator release,2 or in the case of platelet-activating blockade and the contractile state of airway smooth factor due to platelet products.3 muscle is probably the resultant effect of interacting excitatory and inhibitory receptors. Epithelial-derived relaxantfactor It is important to recognize that airway calibre is not only the result of airway smooth muscle tone, but in Recently there has been considerable interest in the asthma it is likely that airway narrowing may also be possibility of a relaxant factor released from airway explained by oedema of the bronchial wall (resulting epithelial cells, which may be analogous to relaxant factor.4 The presence of from microvascular leakage) and to luminal plugging endothelial-derived by copyright. by viscous mucus secretions and extravasated plasma airway epithelium in bovine airways in vitro reduces proteins, which may be produced by a 'soup' of the sensitivity to and maximum contractile effect of mediators released from inflammatory cells, including spasmogens, such as histamine, acetylcholine or mast cells, macrophages and eosinophils.
    [Show full text]
  • Provider- Pain Quick Reference Guide
    A QUICK REFERENCE GUIDE (2019) PBM Academic Detailing Service Posttraumatic Stress Disorder A VA Clinician's Guide to Optimal Treatment of Posttraumatic Stress Disorder (PTSD) VA PBM Academic Detailing Service Real Provider Resources Real Patient Results Your Partner in Enhancing Veteran Health Outcomes VA PBM Academic Detailing Service Email Group [email protected] VA PBM Academic Detailing Service SharePoint Site https://vaww.portal2.va.gov/sites/ad VA PBM Academic Detailing Public Website http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp Table of Contents Abbreviations . 1 PTSD Treatment Decision Aid . 3 VA/DoD 2017 Clinical Practice Guideline: Treatment of PTSD . 4 First-Line Treatment: Trauma-focused Psychotherapies with the Strongest Evidence . 5 First-Line Treatment: Trauma-Focused Psychotherapies with Sufficient Evidence . 6 Comparison of Antidepressants Studied in PTSD . 7 Recommended Antidepressant For PTSD: Dosing . 9 Additional Medications Studied in PTSD: Dosing . 11 Switching Antidepressants . 12 Antidepressants and Sexual Dysfunction . 14 i TOC (continued) Sexual Dysfunction Treatment Strategies . 16 Antidepressants and Hyponatremia . 17 Additional Pharmacotherapy Options for Veterans Refractory to Standard Treatments . 19 Discussing Benzodiazepine Withdrawal . 21 Prazosin Tips . 25 Prazosin Precautions . 26 Managing PTSD Nightmares in Veterans with LUTS Associated with BPH . 27 Other Medications Studied in PTSD-Related Nightmares . 29 References . 30 ii Abbreviations Anti-Ach = anticholinergic
    [Show full text]
  • Oral Phentolamine: an Alpha-1, Alpha-2 Adrenergic Antagonist for the Treatment of Erectile Dysfunction
    International Journal of Impotence Research (2000) 12, Suppl 1, S75±S80 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction I Goldstein1 1Department of Urology, Boston University School of Medicine, Boston, MA, USA Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist which has undergone clinical trials for erectile dysfunction treatment. Biochemical and physiological studies in human erectile tissue have revealed a high af®nity of phentolamine for alpha-1 and alpha-2 adrenergic receptors. Based on pharmacokinetic studies, it is suggested that 30±40 min following oral ingestion of 40 or 80 mg of phentolamine (Vasomax), the mean plasma phentolamine concentrations are suf®cient to occupy the alpha-1 and -2 adrenergic receptors in erectile tissue and thereby result in inhibition of adrenergic-mediated physiologic activity. In large multi-center, placebo-controlled pivotal phase III clinical trials, the mean change in the erectile function domain of the International Index of Erectile Function scores (Questions 1±5 and 15) from screening to the end of treatment was signi®cantly higher following use of active drug (40 mg and 80 mg) compared to placebo. Three to four times as many patients receiving phentolamine reported being satis®ed or very satis®ed compared with those receiving placebo. At doses of 40 mg and 80 mg respectively, 55% and 59% of men were able to achieve vaginal penetration with 51% and 53% achieving penetration on 75% of attempts.
    [Show full text]
  • Therapeutic Drug Class
    BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID EFFECTIVE PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 10/1/12 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL. Version 2012.7b Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]
  • (ADAP) Formulary MAY 2021
    Florida AIDS Drug Assistance Program (ADAP) Formulary MAY 2021 *Indicates controlled substance. Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability. Brand Name (listed for Generic Name Therapeutic Classification Pharmacologic Classification Antiretroviral drugs only) abacavir (ABC) Ziagen Antiretroviral NRTI abacavir/lamivudine (ABC/3TC) Epzicom Antiretroviral NRTI combo abacavir/lamivudine/zidovudine (ABC/3TC/AZT) Trizivir Antiretroviral NRTI combo atazanavir (ATV) Reyataz Antiretroviral PI atazanavir/cobicistat (ATV/COBI) Evotaz Antiretroviral PI/PK Enhancer bictegravir/emtricitabine/tenofovir alafenamide Biktarvy Antiretroviral INSTI/NRTI combo (BIC/FTC/TAF) cabotegravir (CAB) Vocabria Antiretroviral INSTI cabotegravir/rilpivirine (CAB/RPV) Cabenuva Antiretroviral INSTI/NNRTI combo cobicistat (COBI) Tybost Antiretroviral PK Enhancer darunavir (DRV) Prezista Antiretroviral PI darunavir/cobicistat (DRV/COBI) Prezcobix Antiretroviral PI/PK Enhancer darunavir/cobicistat/emtricitabine/tenofovir Symtuza Antiretroviral PI/NRTI combo alafenamide (DRV/COBI/FTC/TAF) dolutegravir (DTG) Tivicay Antiretroviral INSTI dolutegravir / lamivudine (DTG/3TC) Dovato Antiretroviral INSTI/NRTI combo dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) Triumeq Antiretroviral INSTI/NRTI combo dolutegravir/rilpivirine (DTG/RPV) Juluca Antiretroviral INSTI/NNRTI combo doravirine (DOR) Pifeltro Antiretroviral NNRTI doravirine/lamivudine/tenofovir disoproxil fumarate Delstrigo Antiretroviral NNRTI/NRTI combo
    [Show full text]
  • Alpha-Adrenoceptor Antagonists (Alpha-Blockers)
    DRUG CLASSES ALPHA-ADRENOCEPTOR ANTAGONISTS (ALPHA-BLOCKERS) Alpha-blockers are usually used as add-on drugs in difficult to treat hypertension or where other drugs are poorly tolerated. Examples Doxazosin Indoramin Prazosin Terazosin Mechanism of action Commonly used alpha-blockers act selectively at post-ganglionic alpha1-receptors. Selective blockade of peripheral alpha1-receptors leads to vasodilatation and hence reduction in blood pressure. Pharmacokinetics Alpha-blockers are well absorbed after oral administration and undergo extensive hepatic metabolism. The main difference between agents is in elimination half-life: short with indoramin and prazosin and much longer with doxazosin and terazosin. Adverse effects First-dose postural hypotension associated with reflex cardioacceleration and palpitation. Much less common with doxazosin, especially in SR formulation. Vaso-vagal syncope after first dose if unable to mount a rapid heart rate response to hypotension. Caution particularly with terazosin. Headache Oedema Stress incontinence in women Drowsiness with Indoramin 1 Practical issues All alpha-blockers reduce blood pressure. However, doxazosin or terazosin are the preferred options because longer duration of action allows once daily administration. In sustained release formulation, the onset of action of doxazosin is gradual making first- dose hypotension less common. To avoid collapse due to hypotension, it is recomeneded to start terazosin with a low dose given at bedtime. Alpha-blockers are usually used with other agents in the treatment resistant hypertension. In addition to a role in hypertension, alpha-blockers are used to treat benign prostatic hypertrophy. Prazosin is also licensed for the treatment of Raynaud’s syndrome. Alpha- blockers can also be a useful choice in subjects suspected of having phaeochromocytoma.
    [Show full text]
  • A Guide to the Administration of Medicines in the Perioperative
    ......„„.....NHS Grampian Guideline For The Administration Of Medicines In The Pen-Operative Period Co-ordinators: Consultation Group: Approver: Pre-Operative Assessment See Consultation list Medicine Guidelines and Pharmacist Policies Group Signature: Signature: ...i 0 0 a Identifier: Review Date: Date Approved: NHSG/Guid/Peri0p/ May 2022 May 2019 MGPG1026 Uncontrolled when printed Version 3 Executive Sign-Off This document has been endorsed by the Director of Pharmacy and Medicines Management Signature: Title: Guideline for the Administration of Medicines in the Peri- Operative Period Unique Identifier: NHSG/Guid/PeriOp/MGPG1026 Replaces: NHSG/Guid/PeriOp/MGPG697, Version 2 Across NHS Organisation Directorate Clinical Service Sub Boards Wide Department Area This controlled document shall not be copied in part or whole without the express permission of the author or the author’s representative. Lead Author/Co-ordinator: Pre-Operative Assessment Pharmacist Subject (as per document Clinical Guidance registration categories): Key word(s): Peri-operative medication guidance, gastro intestinal system, cardiovascular system, respiratory, central nervous, infections, endocrine, obstetrics, gynaecology, urinary tract, malignant, nutrition, blood, musculoskeletal, joint, corticosteroid treatment, alternative routes, antiepileptic Process Document: Policy, Guideline Protocol, Procedure or Guideline Document application: NHS Grampian Purpose/description: This policy is designed to be used by pharmacy, nursing and medical staff at pre-assessment
    [Show full text]
  • Supplemental Table 2 Revised
    Supplemental Table 2: Additional data validated by the expert panel for inclusion in PIM-Check PIM-Check additional data: Potentially Inappropriate Medications for Patients in Internal Medicine checklist This supplemental table includes PIM-check statements’ additional data. It includes statements’ rational and references and when appropriate recommendations, remarks, and useful links. This tool was validated using a 2-round Delphi method including 40 international experts from Belgium, France, Quebec and Switzerland. Their median level of agreement and useful rating during the second round are indicated for each statement. This is not a replacement for a clinical and biological evaluation by a clinician. The proposals are only applicable in the event there is no patient-specific contraindication. Some drugs listed may not be available in each country. A glossary of all abbreviations used in this tool is available at the end of the table. The *, **, *** symbols refer to information contained in table 3. CARDIOLOGY HEART FAILURE Rational Reduced risk of hospitalisation for heart failure and reduced risk of premature death. Recommendations Suggested dosing regimens: Titration up to effective doses or up to the maximum tolerated dose, while monitoring renal function. Maximum suggested dosing regimens: ACEI: captopril 50 mg TID, enalapril 10–20 mg BID, fosinopril 40 mg QD, lisinopril 20–40 mg QD, perindopril 8–16 mg QD, quinapril 20 mg BID, ramipril 5 mg BID, trandolapril 4 1 mg QD UP ARB: candesartan 32 mg QD, valsartan 160 mg BID, losartan
    [Show full text]
  • Comparison of Alpha Blockers in Treatment of Premature Ejaculation: a Pilot Clinical Trial
    Iranian Red Crescent Medical Journal. 2013 October; 15(10): e13805. DOI: 10.5812.ircmj.13805 Research Article Published Online 2013 October 05. Comparison of Alpha Blockers in Treatment of Premature Ejaculation: A Pilot Clinical Trial 1, * 2 3 1 1 Yigit Akin , Hakan Gulmez , Mutlu Ates , Aliseydi Bozkurt , Baris Nuhoglu 1 Harran University School of Medicine, Department of Urology, Sanliurfa, Turkey 2 Department of Family Medicine, Baskent University School of Medicine, Ankara, Turkey 3 Department of Urology, Afyon Kocatepe University School of Medicine, Afyonkarahisar, Turkey *Corresponding Author : Yigit Akin, Harran University School of Medicine, Department of Urology, 63100, Sanliurfa, Turkey. Tel: +90-5065334999, Fax: +90-4462161819, E-mail: [email protected] Received: ; Revised: ; Accepted: July 25, 2013 August 23, 2013 September 05, 2013 Background: Premature ejaculation (PE) is the most common sexual disorder in men and studies reported prevalence up to 30% (1, 2). PE is not a life-threatening medical condition but it influences the quality of life (QoL). Objectives: The aim of this study was to compare the efficiency, and safety of alpha blocker drugs in the treatment of patients with premature ejaculation (PE). Additionally we investigated the quality of life (QoL) in patients with PE who were treated with alpha blocker drugs. Materials and Methods: This study was a pilot clinical trial. Prospectively documented 108 patients with PE were treated and were followed-up in urology outpatient clinic. All patients were divided into 5 groups according to used alpha blocker agents which were determined by simple randomization. Silodosin 4mg (Group 1, n = 21), tamsulosin hydrochloride 0.4mg (Group 2, n = 23), alfuzosin 10mg (Group 3, n = 22), terazosin 5mg (Group 4, n = 21), doksazosin mesylate 4mg (Group5, n = 21), were used for treatment.
    [Show full text]
  • Faa-Meds.Pdf
    FAA Accepted Medications. FAA FAA Allow Trade Name Drug Classificationti Treatment For Allowed Based On ed Abilify NOT atypical antipsychotic psychosis aripiprazole ALLOWED Accolate antiasthmatic asthma detailed status zafirlukast report from t treating physician Accupril antihypertensive agent high blood pressure hypertension quinapril hypertension evaluation blood pressure Accuretic fixed combination ACE- high blood pressure hypertension ' quinapril inhibitor/diuretic hypertension evaluation HCTZ blood pressure Accutane acne treatment night flying isotretonoin prohibited while le using Aceon ACE inhibitor high blood pressure hypertension ' perindopril erbumine hypertension evaluation t blood pressure Acetaminophen analgesic general pain relief no adverse side numerous label effects brands of OTC products Aciphex gastric acid secreting gastroesophageal reflux status report and rabeprazole inhibitor no adverse side effects Actemra recombinant humanized rheumatoid arthritis NOT Tocilizumab antihuman interleukin 6 ALLOWED receptor Actifed antihistamine allergies 12 hour wait actifed allergic rhinitis before flying common cold Actigall bile acid reduction agent gall stones status report and ursidiol no adverse side effects liver function studies Actonel bone resorption inhibitor osteoporosis status report and risedronate sodium no adverse side effects Actoplus insulin sensitizing agent Diabetes, Type 2 diabetes pioglitazone evaluation metformin Actos oral diabetes agent Diabetes, Type 2 diabetes pioglitazone evaluation Adalat calcium channel
    [Show full text]